BioAtla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. The culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our Conditionally Active Biologics (CAB) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. This improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. BioAtla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.
Employees: 51-200
Total raised: $147.5M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | HBM Partne... | hbmpartner... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.08.2020 | Series D | $72.5M | - |
| 11.01.2016 | - | $45M | - |
| 11.06.2015 | - | $30M | - |
Mentions in press and media 28
| Date | Title | Description | Source |
| 07.03.2024 | BioAtla Announces Poster Presentations at the 2024 American ... | - | globenewsw... |
| 04.11.2022 | BioAtla Announces $65 Million Underwritten Offering of its C... | - | globenewsw... |
| 04.11.2022 | BioAtla Announces $65 Million Underwritten Offering of its C... | /EIN News/ -- SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global cl... | einpresswi... |
| 11.01.2022 | BioAtla Announces Clinical Collaboration with Bristol Myers ... | SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biote... | marketscre... |
| 11.01.2022 | BioAtla : JPM Presentation 2022.pdf | TRANSFORMING CANCER THERAPY January 2022 ` Healthcare Conference Important Notices & Disclaimers... | marketscre... |
| 16.11.2021 | BioAtla Announces Third Quarter 2021 Financial Results And P... | SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biote... | marketscre... |
| 29.09.2021 | BioAtla : Announces Private Placement of 2.7 Million Shares | SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biot... | marketscre... |
| 14.08.2021 | BioAtla : Announces Second Quarter 2021 Financial Results An... | SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biote... | marketscre... |
| 13.08.2021 | BioAtla Announces Second Quarter 2021 Financial Results And ... | prnewswire... | |
| 02.06.2021 | BioAtla : Jefferies Conference – June 2021 | Breakthrough antibody technology to broaden therapeutic window of anti-cancer drugs June 2021 1 Impo... | marketscre... |
Show more